Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas.

Cohen JI, Bollard CM, Khanna R, Pittaluga S.

Leuk Lymphoma. 2008;49 Suppl 1:27-34. doi: 10.1080/10428190802311417. Review.

3.

Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.

Adhikary D, Behrends U, Boerschmann H, Pfünder A, Burdach S, Moosmann A, Witter K, Bornkamm GW, Mautner J.

PLoS One. 2007 Jul 4;2(7):e583. Review.

4.

Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target.

Tse E, Kwong YL.

Exp Mol Med. 2015 Jan 23;47:e136. doi: 10.1038/emm.2014.102. Review.

5.

The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease.

Hsieh WS, Lemas MV, Ambinder RF.

Transpl Infect Dis. 1999 Sep;1(3):204-12. Review.

PMID:
11428990
6.

T-cell therapies for Epstein-Barr virus-associated lymphomas.

El-Bietar J, Bollard C.

Pediatr Hematol Oncol. 2011 Nov;28(8):627-39. doi: 10.3109/08880018.2011.628367. Review.

PMID:
22023461
7.
8.

Immunotherapy for Epstein-Barr virus-associated cancers in children.

Straathof KC, Bollard CM, Rooney CM, Heslop HE.

Oncologist. 2003;8(1):83-98. Review.

9.

Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments.

Neparidze N, Lacy J.

Clin Adv Hematol Oncol. 2014 Jun;12(6):358-71. Review.

PMID:
25003566
10.

Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.

Niller HH, Wolf H, Minarovits J.

Autoimmunity. 2008 May;41(4):298-328. doi: 10.1080/08916930802024772. Review.

PMID:
18432410
11.

Adoptive T-Cell Immunotherapy.

Gottschalk S, Rooney CM.

Curr Top Microbiol Immunol. 2015;391:427-54. doi: 10.1007/978-3-319-22834-1_15. Review.

12.

Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.

Tanner JE, Alfieri C.

Leuk Lymphoma. 1996 May;21(5-6):379-90. Review. Erratum in: Leuk Lymphoma 2001 Nov-Dec;42(6):following 1447.

PMID:
9172802
13.

Epstein-Barr virus (EBV) and lymphomagenesis.

Cesarman E.

Front Biosci. 2002 Feb 1;7:e58-65. Review.

PMID:
11815280
14.

Epstein-Barr virus-associated lymphomas.

Grywalska E, Rolinski J.

Semin Oncol. 2015 Apr;42(2):291-303. doi: 10.1053/j.seminoncol.2014.12.030. Review.

15.

EBV-associated lymphomas in adults.

Roschewski M, Wilson WH.

Best Pract Res Clin Haematol. 2012 Mar;25(1):75-89. doi: 10.1016/j.beha.2012.01.005. Review.

16.

The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.

Savoldo B, Heslop HE, Rooney CM.

Leuk Lymphoma. 2000 Nov;39(5-6):455-64. Review.

PMID:
11342329
17.

Immunotherapy for Epstein-Barr virus-associated tumors.

Comito MA, Sun Q, Lucas KG.

Leuk Lymphoma. 2004 Oct;45(10):1981-7. Review.

PMID:
15370241
18.

Viral lymphomagenesis.

Ahmed N, Heslop HE.

Curr Opin Hematol. 2006 Jul;13(4):254-9. Review.

PMID:
16755222
19.

Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.

Nourse JP, Jones K, Gandhi MK.

Am J Transplant. 2011 May;11(5):888-95. doi: 10.1111/j.1600-6143.2011.03499.x. Review.

Items per page

Supplemental Content

Support Center